Ingrid Halvorsen practises the unglamorous middle of medicine: the medication review, the interaction check, the honest conversation about what a drug will and will not do. She reads a prescribing label the way an editor reads a contract, and she brings that same slow attention to every reader question on Illustris Pharma.
She trained in internal medicine in Oslo, completed a clinical-pharmacology fellowship in Copenhagen, and now splits her week between an inpatient service and a hospital medicines-safety committee. That committee work - deciding which warnings are theoretical and which ones put people in beds - is the instinct she brings to the forum threads.
Across the erectile-dysfunction drugs she leads with the one rule that keeps people out of emergency departments: never combine a PDE5 inhibitor with nitrates, prescription or recreational, because the combined drop in blood pressure can be dangerous. She repeats it whether the question is about food timing, brand switching, or dose, because that is the error that matters most.
On tadalafil, sildenafil and vardenafil she refuses to crown a winner. In registration trials the three land in the same efficacy range; the choice is pharmacology and lifestyle. Tadalafil's long half-life buys spontaneity; sildenafil is the cheapest and longest-studied; vardenafil sits in between and is food-sensitive. She maps onset, duration, the fat-meal effect and the visual-disturbance quirk, then lets the reader and their own prescriber decide.
Her ivermectin answers are deliberately careful. She separates the drug's genuine, decades-deep antiparasitic record - strongyloidiasis, onchocerciasis, scabies - from the pandemic-era antiviral claims that large randomised trials did not support. When a reader mentions travel through Central Africa she walks through Loa loa screening before any dose.
For fluoxetine she spends most of her words on time and expectation: why the first two weeks can feel worse before they feel better, why four to six weeks is the honest window to judge response, and why the drug's unusually long half-life changes how you stop it and how it interacts with tamoxifen and other CYP2D6 substrates.
She cites primary sources - the FDA label, WHO monographs, MedlinePlus, and named trials - whenever a reader asks for something they can check themselves. She thinks a forum answer that points nowhere verifiable is worth very little.
Every reply she writes ends the same way: this is general education from a clinician, not a treatment plan for you. When the honest answer depends on your labs, your other medicines, or an examination she cannot perform, she says so and hands you back to your own prescriber.